Request Free Sample ×
ReportInfographic

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

US Peptic Ulcer Drugs Market

ID: MRFR/Pharma/17953-HCR
100 Pages
Nidhi Mandole
Last Updated: April 06, 2026

US Peptic Ulcer Drugs Market Research Report By Pharmacological Class (Proton Pump Inhibitors (PPIs), Anti-histamines, H2 Antagonists, Antacids, Others) and By Clinical (Gastric Ulcers, Duodenal, Ulcer, Esophageal Ulcer) - Growth & Industry Forecast 2025 To 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

US Peptic Ulcer Drugs Market Infographic
Purchase Options
Compare License
Summary Table of Contents Segmentation Download PDF
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
  2.   1.1 EXECUTIVE SUMMARY
  3.     1.1.1 Market Overview
  4.     1.1.2 Key Findings
  5.     1.1.3 Market Segmentation
  6.     1.1.4 Competitive Landscape
  7.     1.1.5 Challenges and Opportunities
  8.     1.1.6 Future Outlook
  9. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
  10.   2.1 MARKET INTRODUCTION
  11.     2.1.1 Definition
  12.     2.1.2 Scope of the study
  13.       2.1.2.1 Research Objective
  14.       2.1.2.2 Assumption
  15.       2.1.2.3 Limitations
  16.   2.2 RESEARCH METHODOLOGY
  17.     2.2.1 Overview
  18.     2.2.2 Data Mining
  19.     2.2.3 Secondary Research
  20.     2.2.4 Primary Research
  21.       2.2.4.1 Primary Interviews and Information Gathering Process
  22.       2.2.4.2 Breakdown of Primary Respondents
  23.     2.2.5 Forecasting Model
  24.     2.2.6 Market Size Estimation
  25.       2.2.6.1 Bottom-Up Approach
  26.       2.2.6.2 Top-Down Approach
  27.     2.2.7 Data Triangulation
  28.     2.2.8 Validation
  29. 3 SECTION III: QUALITATIVE ANALYSIS
  30.   3.1 MARKET DYNAMICS
  31.     3.1.1 Overview
  32.     3.1.2 Drivers
  33.     3.1.3 Restraints
  34.     3.1.4 Opportunities
  35.   3.2 MARKET FACTOR ANALYSIS
  36.     3.2.1 Value chain Analysis
  37.     3.2.2 Porter's Five Forces Analysis
  38.       3.2.2.1 Bargaining Power of Suppliers
  39.       3.2.2.2 Bargaining Power of Buyers
  40.       3.2.2.3 Threat of New Entrants
  41.       3.2.2.4 Threat of Substitutes
  42.       3.2.2.5 Intensity of Rivalry
  43.     3.2.3 COVID-19 Impact Analysis
  44.       3.2.3.1 Market Impact Analysis
  45.       3.2.3.2 Regional Impact
  46.       3.2.3.3 Opportunity and Threat Analysis
  47. 4 SECTION IV: QUANTITATIVE ANALYSIS
  48.   4.1 Chemicals and Materials, BY Pharmacological Class (USD Million)
  49.     4.1.1 Proton pump inhibitors (PPIs)
  50.     4.1.2 Anti-histamines
  51.     4.1.3 H2 antagonists
  52.     4.1.4 Antacids
  53.     4.1.5 Others
  54.   4.2 Chemicals and Materials, BY Clinical (USD Million)
  55.     4.2.1 Gastric ulcers
  56.     4.2.2 Duodenal ulcers
  57.     4.2.3 Esophageal ulcers
  58. 5 SECTION V: COMPETITIVE ANALYSIS
  59.   5.1 Competitive Landscape
  60.     5.1.1 Overview
  61.     5.1.2 Competitive Analysis
  62.     5.1.3 Market share Analysis
  63.     5.1.4 Major Growth Strategy in the Chemicals and Materials
  64.     5.1.5 Competitive Benchmarking
  65.     5.1.6 Leading Players in Terms of Number of Developments in the Chemicals and Materials
  66.     5.1.7 Key developments and growth strategies
  67.       5.1.7.1 New Product Launch/Service Deployment
  68.       5.1.7.2 Merger & Acquisitions
  69.       5.1.7.3 Joint Ventures
  70.     5.1.8 Major Players Financial Matrix
  71.       5.1.8.1 Sales and Operating Income
  72.       5.1.8.2 Major Players R&D Expenditure. 2023
  73.   5.2 Company Profiles
  74.     5.2.1 Pfizer Inc (US)
  75.       5.2.1.1 Financial Overview
  76.       5.2.1.2 Products Offered
  77.       5.2.1.3 Key Developments
  78.       5.2.1.4 SWOT Analysis
  79.       5.2.1.5 Key Strategies
  80.     5.2.2 AstraZeneca PLC (GB)
  81.       5.2.2.1 Financial Overview
  82.       5.2.2.2 Products Offered
  83.       5.2.2.3 Key Developments
  84.       5.2.2.4 SWOT Analysis
  85.       5.2.2.5 Key Strategies
  86.     5.2.3 Boehringer Ingelheim GmbH (DE)
  87.       5.2.3.1 Financial Overview
  88.       5.2.3.2 Products Offered
  89.       5.2.3.3 Key Developments
  90.       5.2.3.4 SWOT Analysis
  91.       5.2.3.5 Key Strategies
  92.     5.2.4 Takeda Pharmaceutical Company Limited (JP)
  93.       5.2.4.1 Financial Overview
  94.       5.2.4.2 Products Offered
  95.       5.2.4.3 Key Developments
  96.       5.2.4.4 SWOT Analysis
  97.       5.2.4.5 Key Strategies
  98.     5.2.5 Novartis AG (CH)
  99.       5.2.5.1 Financial Overview
  100.       5.2.5.2 Products Offered
  101.       5.2.5.3 Key Developments
  102.       5.2.5.4 SWOT Analysis
  103.       5.2.5.5 Key Strategies
  104.     5.2.6 GlaxoSmithKline PLC (GB)
  105.       5.2.6.1 Financial Overview
  106.       5.2.6.2 Products Offered
  107.       5.2.6.3 Key Developments
  108.       5.2.6.4 SWOT Analysis
  109.       5.2.6.5 Key Strategies
  110.     5.2.7 Sanofi S.A. (FR)
  111.       5.2.7.1 Financial Overview
  112.       5.2.7.2 Products Offered
  113.       5.2.7.3 Key Developments
  114.       5.2.7.4 SWOT Analysis
  115.       5.2.7.5 Key Strategies
  116.     5.2.8 AbbVie Inc (US)
  117.       5.2.8.1 Financial Overview
  118.       5.2.8.2 Products Offered
  119.       5.2.8.3 Key Developments
  120.       5.2.8.4 SWOT Analysis
  121.       5.2.8.5 Key Strategies
  122.   5.3 Appendix
  123.     5.3.1 References
  124.     5.3.2 Related Reports
  125. 6 LIST OF FIGURES
  126.   6.1 MARKET SYNOPSIS
  127.   6.2 US MARKET ANALYSIS BY PHARMACOLOGICAL CLASS
  128.   6.3 US MARKET ANALYSIS BY CLINICAL
  129.   6.4 KEY BUYING CRITERIA OF CHEMICALS AND MATERIALS
  130.   6.5 RESEARCH PROCESS OF MRFR
  131.   6.6 DRO ANALYSIS OF CHEMICALS AND MATERIALS
  132.   6.7 DRIVERS IMPACT ANALYSIS: CHEMICALS AND MATERIALS
  133.   6.8 RESTRAINTS IMPACT ANALYSIS: CHEMICALS AND MATERIALS
  134.   6.9 SUPPLY / VALUE CHAIN: CHEMICALS AND MATERIALS
  135.   6.10 CHEMICALS AND MATERIALS, BY PHARMACOLOGICAL CLASS, 2024 (% SHARE)
  136.   6.11 CHEMICALS AND MATERIALS, BY PHARMACOLOGICAL CLASS, 2024 TO 2035 (USD Million)
  137.   6.12 CHEMICALS AND MATERIALS, BY CLINICAL, 2024 (% SHARE)
  138.   6.13 CHEMICALS AND MATERIALS, BY CLINICAL, 2024 TO 2035 (USD Million)
  139.   6.14 BENCHMARKING OF MAJOR COMPETITORS
  140. 7 LIST OF TABLES
  141.   7.1 LIST OF ASSUMPTIONS
  142.     7.1.1
  143.   7.2 US MARKET SIZE ESTIMATES; FORECAST
  144.     7.2.1 BY PHARMACOLOGICAL CLASS, 2025-2035 (USD Million)
  145.     7.2.2 BY CLINICAL, 2025-2035 (USD Million)
  146.   7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  147.     7.3.1
  148.   7.4 ACQUISITION/PARTNERSHIP
  149.     7.4.1

US Chemicals and Materials Market Segmentation

Chemicals and Materials By Pharmacological Class (USD Million, 2025-2035)

  • Proton pump inhibitors (PPIs)
  • Anti-histamines
  • H2 antagonists
  • Antacids
  • Others

Chemicals and Materials By Clinical (USD Million, 2025-2035)

  • Gastric ulcers
  • Duodenal ulcers
  • Esophageal ulcers

Related Reports

No regional reports available for this market.

No country-specific reports available for this market.

Customer Stories
Case Study Cover Image
Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization ✓ ✓ ✓
Direct Access to Analyst ✓ ✓ ✓
Deliverable Format ✓ ✓ ✓
Platform Access ✗ ✗ ✓
Discount on Next Purchase 10% 15% 15%
Printable Versions ✗ ✗ ✓